Statera Biopharma Announces Pricing of $2.0 Million Registered Direct Offering20220207035919
Statera Biopharma Submits Phase 3 Clinical Trial Protocol to FDA for Investigational Treatment of Pediatric Crohn’s Disease20211229123317
Statera Biopharma Announces First Patient Dosed in Study of STAT-205 for Acute COVID20211220210425
Statera Biopharma Announces FDA Lifts Clinical Hold on Entolimod20211201123341
Statera Biopharma Announces FDA Lifts Clinical Hold on Entolimod
December 1, 2021
Statera Biopharma Provides Third Quarter 2021 Financial and Corporate Update20211115210323
Statera Biopharma, Inc. to Report Third Quarter 2021 Financial Results20211109123408
Statera Biopharma Honors Pancreatic Cancer Awareness Month20211101113344
Statera Biopharma Honors Pancreatic Cancer Awareness Month
November 1, 2021
Statera Biopharma, Inc. Announces Institutional Review Board Approves Study of STAT-205 for Acute COVID-1920211019113343
Statera Biopharma, Inc. to Participate in the A.G.P. Biotech and Specialty Pharma Conference20211006113325
Statera Biopharma Announces CEO Mike Handley to Speak During Virtual B & T Cell-Mediated Autoimmune Disease Drug Development Summit20211005115225